Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
| Alecensaro | Alectinib | Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
| Leqembi | lecanemab | Alzheimer’s disease | Pending | |||
| Olumiant | baricitinib | Alopecia areata, severe | Active |
Last Updated : May 9, 2024